Expanded Access Neoantigen Vaccine in Solid Tumors

See also
Status	Clinical Trial	Phase
Terminated	`NCT04551885` - FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors	Phase 1
Completed	`NCT05054348` - First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors	Phase 1
Active, not recruiting	`NCT04474470` - A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer	Phase 1/Phase 2
Recruiting	`NCT06088004` - Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 Monotherapy in Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT05055609` - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1
Completed	`NCT04020185` - Safety and Efficacy Study of IMSA101 in Refractory Malignancies	Phase 1/Phase 2
Withdrawn	`NCT05071846` - MVX-ONCO-2 in Advanced Solid Tumors	Phase 1
Recruiting	`NCT05607199` - A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics	Phase 1
Active, not recruiting	`NCT04552288` - Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies	Phase 2
Active, not recruiting	`NCT06026254` - A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial	Phase 1
Recruiting	`NCT06144671` - GT201 Injection For The Treatment Of Advanced Solid Tumors	Phase 1/Phase 2
Recruiting	`NCT06032845` - Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Solid Tumors (CASTLE-11)	Phase 2
Not yet recruiting	`NCT06398418` - R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors	Phase 1
Recruiting	`NCT05276284` - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy	Phase 1/Phase 2
Recruiting	`NCT04121442` - Isunakinra Alone and in Combination With a PD-1/PD-L1 Inhibitor in Patients With Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04221204` - A Monotherapy in Subjects With Advanced Solid Tumors	Phase 1
Terminated	`NCT03992326` - Adoptive Transfer Of Autologous Tumor-Infiltrating Lymphocytes in Solid Tumors	Phase 1
Terminated	`NCT05435339` - A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy	Phase 1/Phase 2
Recruiting	`NCT04981119` - Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Recruiting	`NCT06075849` - Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent	Phase 1

NCT number	NCT03914872
Study type	Expanded Access
Source	Washington University School of Medicine
Contact
Status	No longer available
Phase

Expanded Access Neoantigen Vaccine in Solid Tumors

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms